GenBioPro declines to comment on Hawley's bill to ban mifepristone
GenBioProManufacturer of generic mifepristone, in an emailed reply from its public relations firm, Feldman Strategies
GenBioPro, which makes a generic version of mifepristone, declined to comment on Sen. Josh Hawley's bill to ban the drug, in an emailed reply sent on its behalf by its public relations firm.
“At this time, the company prefers not to comment.”
Emailed statement
Read the full email
Hi Ben, Reaching out for GenBioPro. At this time, the company prefers not to comment. Thanks, Emma
Where this statement fits
Should Congress ban the abortion pill, mifepristone, as Josh Hawley has proposed?
On March 11, 2026, Senator Josh Hawley introduced the Safeguarding Women from Chemical Abortion Act, which would withdraw the Food and Drug Administration's approval of mifepristone for pregnancy termination, make distributing and labeling the drug for that purpose violations of the Federal Food, Drug and Cosmetic Act, and let women who say chemical abortion harmed them sue its manufacturers. Mifepristone has been approved in the United States since 2000 and is used in a large majority of American abortions. Hawley argues a national ban is the only remedy because the drug can be mailed into states whose own laws restrict abortion. The bill drew seven Republican cosponsors but has not moved out of the Senate Health, Education, Labor and Pensions Committee. On September 16, 2026, Hawley unveiled a four-page "Declaration for Life" and began asking officeholders and candidates to sign it as a commitment to ban the drug. The dispute is over whether Congress should enact that ban.
Source and context
Emailed statement
Emailed reply from GenBioPro to Dispute Index declining to comment on Hawley's mifepristone bill
Hi Ben, Reaching out for GenBioPro. At this time, the company prefers not to comment. Thanks, Emma
About this source
Emailed reply sent on behalf of GenBioPro by Emma Thomas of its public relations firm, Feldman Strategies, to a Dispute Index request for the company's response to Sen. Josh Hawley's bill to ban mifepristone. The company declined to comment.
Archived copy (opens in a new tab)Before the quotation
Dispute Index wrote to GenBioPro's media address on September 25, 2026, noting that the bill would withdraw the drug's approval for ending a pregnancy and let women who say it harmed them sue manufacturers, and asked for the company's response.
After the quotation
Dispute Index had not found a public statement from GenBioPro on the bill when it wrote on September 25.
How this statement is classified
The label describes this statement's response within the context above.
Why this label?
The reference point is Sen. Josh Hawley's proposal to ban mifepristone by withdrawing the drug's approval for ending a pregnancy. Asked for its response to the bill, GenBioPro said through its public relations firm that it prefers not to comment at this time, so we used Explicitly stayed out. The closest competing label is a finding that this is not a position event at all; it loses because the company was asked directly for its position and declined to give one.
- Recorded on
- Published here
More from this case
Read the full caseHawley urges FDA action on abortion-drug availability
“We've got to make sure that she is committed to ending the abortion drugs' availability in the state of Missouri and every other state. That they're going to put back in place the safety restrictions and they're going to follow the law.”Read statement
Tony Perkins says the Republican Party has "lost its voice" on abortion and credits Hawley with filling the vacuum
“Unfortunately the Republican Party has lost its voice on the life issue and in that vacuum there are leaders that are stepping forward like Sen. Hawley calling upon the church, communities and the country to step up on behalf of the unborn.”Read statement
Hawley unveils the "Declaration for Life" and asks candidates to commit to banning the abortion drug
“This Declaration for Life, written by pastors, is calling on everyday Christians across America to stand for life and confront the scourge of chemical abortion.”Read statement
Share or embed this statement
The embed keeps its attribution link to The Dispute Index. Credit the image to The Dispute Index and link to the statement page.
Cite this record
- Publisher
- The Dispute Index
- Title
- GenBioPro declines to comment on Hawley's bill to ban mifepristone
- First published
- Last updated
- Permalink
- https://disputeindex.com/events/5736-genbiopro-which-makes-a-generic-version-of-mifepristone
Last updated marks the most recent saved version of this published statement.
The Dispute Index. "GenBioPro declines to comment on Hawley's bill to ban mifepristone". First published: 2026-10-14. Last updated: 2026-10-14. https://disputeindex.com/events/5736-genbiopro-which-makes-a-generic-version-of-mifepristone